Syndesi Therapeutics is a biotech company developing small molecules targeting SV2A to modulate synaptic transmission for Alzheimer's and cognitive disorders
Syndesi Therapeutics is a biotech company developing small molecules targeting SV2A to modulate synaptic transmission for Alzheimer's and cognitive disorders. The platform, exclusively licensed from UCB, advances lead compounds into Phase 1 trials demonstrating safety and biomarker modulation.